Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIRCEA O BADARA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1801877865
CMS profile
500107
Location
NEW BRITAIN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,795.09

93 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,651.60 91
Education $143.49 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIRCEA O BADARA

NPI 1801877865 · CMS profile ID 500107

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEW BRITAIN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801877865?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801877865?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801877865?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1801877865?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

93 matching records · $1,795.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 93 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–93 of 93.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Covis Pharma GmBH $26.7108/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847701085 CMS
GENZYME CORPORATION $20.3908/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588667 CMS
GENZYME CORPORATION $22.9508/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588665 CMS
AstraZeneca Pharmaceuticals LP $14.5608/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829984923 CMS
Regeneron Healthcare Solutions, Inc. $11.3008/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809556931 CMS
AstraZeneca Pharmaceuticals LP $17.8007/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829495491 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5307/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763316554 CMS
GlaxoSmithKline, LLC. $14.2707/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803146827 CMS
GENZYME CORPORATION $18.3907/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588661 CMS
Mallinckrodt Hospital Products Inc. $16.8907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845345195 CMS
GENZYME CORPORATION $12.6307/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588651 CMS
GlaxoSmithKline, LLC. $17.0007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802428687 CMS
Eisai Inc. $11.4206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817976789 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.7606/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763316556 CMS
GENZYME CORPORATION $19.6706/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588643 CMS
SANOFI-AVENTIS U.S. LLC $43.5006/24/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843588687 CMS
HARMONY BIOSCIENCES LLC $31.6606/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853072951 CMS
AstraZeneca Pharmaceuticals LP $14.9506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829634009 CMS
GlaxoSmithKline, LLC. $18.0006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802987519 CMS
Mallinckrodt Hospital Products Inc. $12.8206/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845345193 CMS
Novartis Pharmaceuticals Corporation $14.6706/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596247 CMS
JAZZ PHARMACEUTICALS INC. $24.9806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845627631 CMS
Regeneron Healthcare Solutions, Inc. $17.6106/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809556929 CMS
GlaxoSmithKline, LLC. $19.3205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802026259 CMS
Philips Electronics North America Corporation $13.6905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853248055 CMS
Eisai Inc. $12.6105/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817925867 CMS
Advanced Respiratory, Inc $18.7105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853541145 CMS
Novartis Pharmaceuticals Corporation $13.9405/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596245 CMS
GlaxoSmithKline, LLC. $20.4005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803149123 CMS
GlaxoSmithKline, LLC. $8.9104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803070717 CMS
Mylan Specialty L.P. $22.6504/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965413663 CMS
AstraZeneca Pharmaceuticals LP $15.7604/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829609753 CMS
GlaxoSmithKline, LLC. $20.8704/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802989799 CMS
GlaxoSmithKline, LLC. $20.8704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802182263 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.2204/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763316558 CMS
AstraZeneca Pharmaceuticals LP $85.8903/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829392559 CMS
GlaxoSmithKline, LLC. $19.3503/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802909133 CMS
AstraZeneca Pharmaceuticals LP $23.5403/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829801167 CMS
JAZZ PHARMACEUTICALS INC. $17.5103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845625823 CMS
GlaxoSmithKline, LLC. $15.8503/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802846521 CMS
JAZZ PHARMACEUTICALS INC. $19.5602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845624745 CMS
GlaxoSmithKline, LLC. $23.0401/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802589051 CMS
GlaxoSmithKline, LLC. $21.5401/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801727033 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.31 13
PY2020 $92.66 6
PY2021 $1,795.09 93
PY2022 $2,319.82 125
PY2023 $2,413.94 125
PY2024 $3,278.14 147
PY2025 $3,530.76 162

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $415,289.17 38
PY2024 Principal investigator $356,161.99 41
PY2023 Principal investigator $217,952.31 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $1,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670234
Principal investigator 1 CSL Behring $1,750.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670236
Principal investigator 1 CSL Behring $2,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670238
Principal investigator 1 CSL Behring $2,750.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670240
Principal investigator 1 CSL Behring $12,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670242
Principal investigator 1 Genentech, Inc. $3,306.00 12/12/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615602
Principal investigator 1 Genentech, Inc. $2,250.00 11/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615553
Principal investigator 1 Genentech, Inc. $400.00 10/15/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615538
Principal investigator 1 Genentech, Inc. $62,201.00 09/24/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,748.97 08/22/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185551177
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,750.00 08/07/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185551181
Principal investigator 1 Genentech, Inc. $456.26 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615434
Principal investigator 1 Genentech, Inc. $400.00 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615441
Principal investigator 1 Genentech, Inc. $5,194.00 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615462
Principal investigator 1 Genentech, Inc. $1,274.00 06/18/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615352
Principal investigator 1 Genentech, Inc. $243.54 06/13/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615219
Principal investigator 1 Genentech, Inc. $728.00 06/13/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615356
Principal investigator 1 Genentech, Inc. $120.97 05/30/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615309
Principal investigator 1 Genentech, Inc. $1,508.00 05/16/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615382
Principal investigator 1 Genentech, Inc. $58,741.00 05/16/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615397
Principal investigator 1 Genentech, Inc. $3,039.28 05/07/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615329
Principal investigator 1 Genentech, Inc. $207.65 04/30/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615234
Principal investigator 1 Genentech, Inc. $3,458.00 03/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614944
Principal investigator 1 Genentech, Inc. $5,961.00 03/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614829
Principal investigator 1 Genentech, Inc. $767.71 02/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615003
Principal investigator 1 Genentech, Inc. $3,081.47 02/19/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615132
Principal investigator 1 Genentech, Inc. $1,750.00 02/14/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614961
Principal investigator 1 Genentech, Inc. $1,987.00 02/12/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615086
Principal investigator 1 Genentech, Inc. $245.14 02/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614929
Principal investigator 1 Genentech, Inc. $37,676.00 02/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615040
Principal investigator 1 Genentech, Inc. $419.18 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614867
Principal investigator 1 Genentech, Inc. $122.57 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614954
Principal investigator 1 Genentech, Inc. $122.57 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615076
Principal investigator 1 Genentech, Inc. $655.66 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615091
Principal investigator 1 Genentech, Inc. $3,232.00 01/29/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615120
Principal investigator 1 Genentech, Inc. $4,048.00 01/22/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614906
Principal investigator 1 Genentech, Inc. $10,006.00 01/14/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615045
Principal investigator 1 AstraZeneca Pharmaceuticals LP $106,188.20 01/03/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185551179